The Delhi High Court on Friday gave a green signal to pharmaceutical companies Biocon and Mylan to manufacture and sell biosimilar drug Trastuzumab for early breast and metastatic gastric cancer.
The court had earlier allowed them to sell its biosimilar drug for metastatic breast cancer.
Earlier the Delhi High Court had allowed Biocon and Mylan to market their product without any reference to Roche's product or biosimilarity.
As a result, Biocon and Mylan, which were facing a challenge from Roche for sale of the biosimilar drug for three indications-metastatic breast cancer, early breast cancer and gastric cancer-would now be free to sell these drugs.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app